Michelle Hermiston, MD, PhD

Title(s)Professor, Pediatrics
SchoolSchool of Medicine
Address550 16th Street, #4507
San Francisco CA 94158
Phone415-476-3831
ORCID ORCID Icon0000-0003-1790-2679 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of California, San FranciscoResidency Pediatrics
    University of California, San Francisco, CA2019Diversity, Equity, and Inclusion Champion Training

    Collapse Overview 

    Collapse Research 
    Collapse Research Activities and Funding
    Improving risk allocation and developing novel therapies for children with T-ALL
    NIH R01CA193776May 4, 2015 - Apr 30, 2021
    Role: Co-Principal Investigator
    Interplay of Innate and Adaptive Immunity in Lupus Pathogenesis
    NIH R01AI089831Jun 1, 2010 - May 31, 2015
    Role: Principal Investigator
    Role of CD45 in Hematopoiesis and Lymphomagenesis
    NIH K08CA098418Jul 11, 2003 - Jun 30, 2007
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Durable immunity to EBV after rituximab and third-party LMP-specific T cells: a Children's Oncology Group study. Blood Adv. 2024 Mar 12; 8(5):1116-1127. Wistinghausen B, Toner K, Barkauskas DA, Jerkins LP, Kinoshita H, Chansky P, Pezzella G, Saguilig L, Hayashi RJ, Abhyankar H, Scull B, Karri V, Tanna J, Hanley P, Hermiston ML, Allen CE, Bollard CM. PMID: 38163318; PMCID: PMC10909726.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    2. MRD at the End of Induction and EFS in T-cell Lymphoblastic Lymphoma: Children's Oncology Group Trial AALL1231. Blood. 2024 Mar 08. Hayashi RJ, Hermiston ML, Wood BL, Teachey DT, Devidas M, Chen Z, Annett RD, Asselin BL, August K, Cho S, Dunsmore KP, Freedman JL, Galardy PJ, Harker-Murray P, Horton TM, Jaju A, Lam A, Messinger YH, Miles RR, Okada M, Patel S, Schafer ES, Schechter T, Shimano KA, Singh N, Steele A, Sulis ML, Vargas S, Winter SS, Wood C, Zweider-McKay PA, Loh ML, Hunger SP, Raetz EA, Bollard CM, Allen CE. PMID: 38457359.
      View in: PubMed   Mentions:    Fields:    
    3. Old is gold: frontline etoposide for pHLH. Blood. 2024 Mar 07; 143(10):836-838. Gulati N, Hermiston ML. PMID: 38451514.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    4. A roadmap to establishing global oncology as a priority initiative within a National Cancer Institute-designated cancer center. J Natl Cancer Inst. 2024 Mar 07; 116(3):345-351. Van Loon K, Breithaupt L, Ng D, DeBoer RJ, Buckle GC, Bialous S, Hiatt RA, Volberding P, Hermiston ML, Ashworth A. PMID: 38060289; PMCID: PMC10919326.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    5. Evaluation of Culture Conducive to Academic Success by Gender at a Comprehensive Cancer Center. Oncologist. 2024 Mar 04; 29(3):e351-e359. Keenan BP, Sibley A, Zhang L, Westring AF, Velazquez AI, Bank EM, Bergsland EK, Boreta L, Conroy P, Daras M, Hermiston M, Hsu G, Paris PL, Piawah S, Sinha S, Sosa JA, Tsang M, Venook AP, Wong M, Yom SS, Van Loon K. PMID: 37440206; PMCID: PMC10911925.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    6. Real-world treatment patterns and outcomes in patients with primary hemophagocytic lymphohistiocytosis treated with emapalumab. Blood Adv. 2024 Mar 01. Chandrakasan S, Jordan MB, Baker A, Behrens EM, Bhatla D, Chien M, Eckstein OS, Henry MM, Hermiston ML, Hinson A, Leiding JW, Oladapo A, Patel SA, Pednekar P, Ray A, Dávila Saldaña BJ, Sarangi SN, Walkovich K, Yee JD, Zoref-Lorenz A, Allen CE. PMID: 38429096.
      View in: PubMed   Mentions:    Fields:    
    7. A maelstrom of migrating monocytes drives neurodegeneration. Immunity. 2023 Dec 12; 56(12):2677-2678. Coufal NG, Hermiston ML. PMID: 38091948.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    8. Risk Factors and Outcomes for Hematotoxicity Following Tisagenlecleucel for Pediatric B-Acute Lymphoblastic Leukemia. Blood. 2023 Nov 28; 142(Supplement 1):2133. McNerney MK, Fabrizio FV, Talleur TA, Lim LS, Dreyzin DA, Baggott BC, Vatsayan VA, Rossoff RJ, Prabhu PS, Pacenta PH, Phillips PC, Talano TJ, Moskop MA, Verneris VM, Myers MD, Karras KN, Bonifant BC, Qayed QM, Hermiston HM, Satwani SP, Krupski KC, Keating KA, Baumeister BS, Chinnabhandar CV, Egeler EE, Curran CK, Mackall MC, Laetsch LT, Schultz SL, Naik NS. .
      View in: Publisher Site   Mentions:
    9. Framework humanization optimizes potency of anti-CD72 nanobody CAR-T cells for B-cell malignancies. J Immunother Cancer. 2023 11 24; 11(11). Temple WC, Nix MA, Naik A, Izgutdina A, Huang BJ, Wicaksono G, Phojanakong P, Serrano JAC, Young EP, Ramos E, Salangsang F, Steri V, Xirenayi S, Hermiston M, Logan AC, Stieglitz E, Wiita AP. PMID: 38007238; PMCID: PMC10680002.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    10. Pre-and post-HSCT use of TKI therapy for fusion-driven B-ALL: A case series of five pediatric, adolescent and young adult patients. Cancer Rep (Hoboken). 2023 Dec; 6(12):e1901. Shumock SS, Temple WC, Marinoff A, Aaronson K, Southworth E, Xirenayi S, Lee AG, Leung SG, Sweet-Cordero EA, Hermiston M, Higham C, Stieglitz E. PMID: 37933765; PMCID: PMC10728537.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    11. Mediport use as an acceptable standard for CAR T cell infusion. Front Immunol. 2023; 14:1239132. Eylon M, Prabhu S, John S, King MJM, Bhatt D, Curran KJ, Erickson C, Karras NA, Phillips CL, Satwani P, Hermiston M, Southworth E, Baumeister SHC, Talano JA, MacMillan ML, Rossoff J, Bonifant CL, Myers GD, Rouce RH, Toner K, Driscoll TA, Katsanis E, Salzberg DB, Schiff D, De Oliveira SN, Capitini CM, Pacenta HL, Pfeiffer T, Shah NC, Huynh V, Skiles JL, Fraint E, McNerney KO, Quigg TC, Krueger J, Ligon JA, Fabrizio VA, Baggott C, Laetsch TW, Schultz LM. PMID: 37965315; PMCID: PMC10642031.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    12. Tisagenlecleucel utilisation and outcomes across refractory, first relapse and multiply relapsed B-cell acute lymphoblastic leukemia: a retrospective analysis of real-world patterns. EClinicalMedicine. 2023 Nov; 65:102268. Barsan V, Li Y, Prabhu S, Baggott C, Nguyen K, Pacenta H, Phillips CL, Rossoff J, Stefanski H, Talano JA, Moskop A, Baumeister S, Verneris MR, Myers GD, Karras NA, Cooper S, Qayed M, Hermiston M, Satwani P, Krupski C, Keating A, Fabrizio V, Chinnabhandar V, Kunicki M, Curran KJ, Mackall CL, Laetsch TW, Schultz LM. PMID: 37954907; PMCID: PMC10632672.
      View in: PubMed   Mentions:
    13. Hemophagocytic lymphohistiocytosis and clonally related T-cell malignancies in a pediatric patient. Pediatr Blood Cancer. 2023 Dec; 70(12):e30677. Meyer LK, Huang I, Huang BJ, Chung JH, Pawar A, Hermiston ML, Loh ML, Ohgami RS, Ruiz-Cordero R, Bhargava P, Marinoff AE. PMID: 37702960.
      View in: PubMed   Mentions:    Fields:    
    14. Mature B-cell lymphomas in adolescents and young adults. EJHaem. 2023 Nov; 4(4):912-920. El-Mallawany NK, Giulino-Roth L, Burke JM, Hermiston M, Allen CE. PMID: 38024628; PMCID: PMC10660408.
      View in: PubMed   Mentions:
    15. Children's Oncology Group's 2023 blueprint for research: Non-Hodgkin lymphoma. Pediatr Blood Cancer. 2023 09; 70 Suppl 6:e30565. El-Mallawany NK, Alexander S, Fluchel M, Hayashi RJ, Lowe EJ, Giulino-Roth L, Wistinghausen B, Hermiston M, Allen CE, COG NHL Committee. PMID: 37449925; PMCID: PMC10577684.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    16. Challenging T-ALL to IL-7Rp dual inhibition. Blood. 2023 07 13; 142(2):124-126. Fries C, Hermiston ML. PMID: 37440269.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    17. HLH-like toxicities predict poor survival after the use of tisagenlecleucel in children and young adults with B-ALL. Blood Adv. 2023 06 27; 7(12):2758-2771. McNerney KO, Si Lim SJ, Ishikawa K, Dreyzin A, Vatsayan A, Chen JJ, Baggott C, Prabhu S, Pacenta HL, Philips C, Rossoff J, Stefanski HE, Talano JA, Moskop A, Verneris M, Myers D, Karras NA, Brown P, Bonifant CL, Qayed M, Hermiston M, Satwani P, Krupski C, Keating AK, Baumeister SHC, Fabrizio VA, Chinnabhandar V, Egeler E, Mavroukakis S, Curran KJ, Mackall CL, Laetsch TW, Schultz LM. PMID: 36857419; PMCID: PMC10275701.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    18. How I treat newly diagnosed and refractory T-cell acute lymphoblastic lymphoma in children and young adults. Blood. 2023 06 22; 141(25):3019-3030. Si Lim SJ, Ford JB, Hermiston ML. PMID: 37018730.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    19. How I approach B-lymphoblastic lymphoma in children. Pediatr Blood Cancer. 2023 Aug; 70(8):e30401. Devine KJ, Fries C, Hermiston M, Wistinghausen B. PMID: 37158503.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    20. Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed/refractory acute lymphoblastic leukemia. Haematologica. 2023 03 01; 108(3):747-760. Wayne AS, Huynh V, Hijiya N, Rouce RH, Brown PA, Krueger J, Kitko CL, Ziga ED, Hermiston ML, Richards MK, Baruchel A, Schuberth PC, Rossi J, Zhou L, Goyal L, Jain R, Vezan R, Masouleh BK, Lee DW. PMID: 36263840; PMCID: PMC9973494.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    21. Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium. Blood Adv. 2023 02 28; 7(4):541-548. Stefanski HE, Eaton A, Baggott C, Rossoff J, Verneris MR, Prabhu S, Pacenta HL, Phillips CL, Talano JA, Moskop A, Margossian SP, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston M, Satwani P, Krupski MC, Keating AK, Wilcox R, Rabik CA, Fabrizio VA, Chinnabhandar V, Goksenin AY, Curran KJ, Mackall CL, Laetsch TW, Schultz LM. PMID: 35938863; PMCID: PMC9979765.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    22. Diagnosis and management of lymphoblastic lymphoma in children, adolescents and young adults. Best Pract Res Clin Haematol. 2023 03; 36(1):101449. Temple WC, Mueller S, Hermiston ML, Burkhardt B. PMID: 36907639.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    23. Allowing Relationships to Unfold: Consult Reason and Topics Discussed in Initial and Subsequent Palliative Care Visits Among Children Who Died From Relapsed/Refractory Cancer. J Pediatr Hematol Oncol Nurs. 2023 May-Jun; 40(3):170-177. Root MC, Koo J, Collins G, Penumarthy NL, Hermiston M, Bogetz JF. PMID: 36726328; PMCID: PMC10331083.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    24. Pre-clerkship Teaching and Learning in the Virtual Learning Environment: Lessons Learned and Future Directions. Med Sci Educ. 2022 Nov 19; 1-5. Sewell JL, Joshi M, Thanh C, Apollon C, Austin E, Burke C, Cornes S, Davis JA, Hermiston M. PMID: 36439405; PMCID: PMC9676858.
      View in: PubMed   Mentions:
    25. Correlation of Minimal Residual Disease (MRD) at the End of Induction (EOI) and Event Free Survival (EFS) in T-Cell Lymphoblastic Lymphoma (T-LL), a Report from the Children's Oncology Group (COG) Trial AALL1231. Blood. 2022 Nov 15; 140(Supplement 1):6387-6389. Hayashi HR, Hermiston HM, Teachey TD, Devidas DM, Wood WB, Chen CZ, Annett AR, Asselin AB, August AK, Cho CS, Dunsmore DK, Freedman FJ, Galardy GP, Harker-Murray HP, Horton HT, Jaju JA, Lam LA, Messinger MY, Miles MR, Okada OM, Patel PS, Schafer SE, Schechter-Finkelstein ST, Shimano SK, Singh SN, Steele SA, Sulis SM, Vargas VS, Winter WS, Wood WC, Zweidler-McKay ZP, Loh LM, Hunger HS, Raetz RE, Bollard BC, Allen AC. .
      View in: Publisher Site   Mentions:
    26. Obesity Associates with Inferior Outcomes and Toxicity in Pediatric and Young Adult Patient with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Treated with Commercially Manufactured Tisagenlecleucel. Blood. 2022 Nov 15; 140(Supplement 1):10419-10421. Ross RA, Baggott BC, Prabhu PS, Pacenta PH, Philips PC, Rossoff RJ, Stefanski SH, Talano TJ, Moskop MA, Baumeister BS, Verneris VM, Myers MG, Karras KN, Qayed QM, Hermiston HM, Satwani SP, Krupski KC, Keating KA, Wilcox WR, Fabrizio FV, Chinnabhandar CV, Curran CK, Mackall MC, Laetsch LT, Althouse AS, Maude MS, Henry HC, Schultz SL, Skiles SJ. .
      View in: Publisher Site   Mentions:
    27. A Transcriptional Classifier Identifies Pediatric T-Cell Acute Lymphoblastic Leukemias at High Risk for End of Induction Minimal Residual Disease. Blood. 2022 Nov 15; 140(Supplement 1):1722-1723. Meyer ML, Roy RR, Pölönen PP, Elsayed EA, Huang HB, Kimura KS, Delgado-Martin DC, Vincent VT, Ryan RT, Wood WB, Chen CZ, Liu LY, Zhang ZJ, Horton HT, Loh LM, Devidas DM, Raetz RE, Hayashi HR, Winter WS, Dunsmore DK, Hunger HS, Pounds PS, Hermiston HM, Yang YJ, Mullighan MC, Teachey TD, Olshen OA. .
      View in: Publisher Site   Mentions:
    28. Standard Cytogenetic Risk Stratification Is Not Predictive of CD19 CAR Outcomes and Impact of Disease Burden Varies between Cytogenetic Risk Groups. Blood. 2022 Nov 15; 140(Supplement 1):10386-10388. Molina MJ, Chinnabhandar CV, Fabrizio FV, Kunicki KM, Pacenta PH, Rossoff RJ, Stefanski SH, Talano TJ, Moskop MA, Verneris VM, Myers MG, Karras KN, Baggott BC, Qayed QM, Hermiston HM, Satwani SP, Krupski KC, Keating KA, Baumeister BS, Curran CK, Mackall MC, Laetsch LT, Schultz SL, Smith SS. .
      View in: Publisher Site   Mentions:
    29. Peripheral Blast Count at Apheresis Acts Independent of Disease Burden As a Risk Factor for Survival Following Tisagenlecleucel in Children and Young Adults. Blood. 2022 Nov 15; 140(Supplement 1):4661-4663. Fabrizio FV, Miller MK, Baggott BC, Prabhu PS, Pacenta PH, Phillips PC, Rossoff RJ, Stefanski SH, Talano TJ, Moskop MA, Baumeister BS, Myers MG, Karras KN, Brown BP, Qayed QM, Hermiston HM, Satwani SP, Krupski KC, Wilcox WR, Chinnabhandar CV, Curran CK, Mackall MC, Laetsch LT, Keating KA, Verneris VM, Schultz SL. .
      View in: Publisher Site   Mentions:
    30. 010 CD72 NANOBODY CAR-T CELLS HAVE POTENT ANTITUMOR EFFICACY IN B CELL MALIGNANCIES. Leukemia Research. 2022 Oct 1; 121:s8. Temple TW, Nix NM, Wicaksono WG, Wang WD, Phojanakong PP, Steri SV, Hann HB, Hermiston HM, Wiita WA. .
      View in: Publisher Site   Mentions:
    31. 049 A TARGETED GENE EXPRESSION CLASSIFIER IDENTIFIES PEDIATRIC T-ALL PATIENTS AT HIGH RISK FOR END INDUCTION MINIMAL RESIDUAL DISEASE POSITIVITY. Leukemia Research. 2022 Oct 1; 121:s34-s35. Meyer ML, Roy RR, Huang HB, Kimura KS, Polonen PP, Delgado-Martin DC, Vincent VT, Ryan RT, Wood WB, Liu LY, Zhang ZJ, Mullighan MC, Horton HT, Loh LM, Devidas DM, Raetz RE, Hayashi HR, Winter WS, Dunsmore DK, Hunger HS, Teachey TD, Hermiston HM, Olshen OA. .
      View in: Publisher Site   Mentions:
    32. Outcomes After Nonresponse and Relapse Post-Tisagenlecleucel in Children, Adolescents, and Young Adults With B-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2023 01 10; 41(2):354-363. Schultz LM, Eaton A, Baggott C, Rossoff J, Prabhu S, Keating AK, Krupski C, Pacenta H, Philips CL, Talano JA, Moskop A, Baumeister SHC, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston M, Satwani P, Wilcox R, Rabik CA, Fabrizio VA, Chinnabhandar V, Kunicki M, Mavroukakis S, Egeler E, Li Y, Mackall CL, Curran KJ, Verneris MR, Laetsch TW, Stefanski H. PMID: 36108252; PMCID: PMC9839307.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    33. Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia. Blood Adv. 2022 07 26; 6(14):4251-4255. Moskop A, Pommert L, Baggott C, Prabhu S, Pacenta HL, Phillips CL, Rossoff J, Stefanski HE, Talano JA, Margossian SP, Verneris MR, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston ML, Satwani P, Krupski C, Keating AK, Wilcox R, Rabik CA, Fabrizio VA, Chinnabhandar V, Goksenin AY, Curran KJ, Mackall CL, Laetsch TW, Guest EM, Breese EH, Schultz LM. PMID: 35580324; PMCID: PMC9327536.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    34. Anatomy of a Consult: How a Multidisciplinary Pediatric Stem Cell Transplant Team Considers Specialty Palliative Care Consultation (GP722). Journal of Pain and Symptom Management. 2022 Jun 1; 63(6):1123-1124. Collins CG, Beaman BH, Ho HA, Hermiston HM, Cohen CH, Dzeng DE. .
      View in: Publisher Site   Mentions:
    35. International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults. Blood. 2022 04 28; 139(17):2601-2621. Goyal G, Tazi A, Go RS, Rech KL, Picarsic JL, Vassallo R, Young JR, Cox CW, Van Laar J, Hermiston ML, Cao XX, Makras P, Kaltsas G, Haroche J, Collin M, McClain KL, Diamond EL, Girschikofsky M. PMID: 35271698.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansCells
    36. Inhibition of the Sec61 translocon overcomes cytokine-induced glucocorticoid resistance in T-cell acute lymphoblastic leukaemia. Br J Haematol. 2022 07; 198(1):137-141. Meyer LK, Delgado-Martin C, Sharp PP, Huang BJ, McMinn D, Vincent TL, Ryan T, Horton TM, Wood BL, Teachey DT, Taunton J, Kirk CJ, Hermiston ML. PMID: 35434798; PMCID: PMC9322670.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    37. Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy. Blood Adv. 2022 04 12; 6(7):1961-1968. Fabrizio VA, Boelens JJ, Mauguen A, Baggott C, Prabhu S, Egeler E, Mavroukakis S, Pacenta H, Phillips CL, Rossoff J, Stefanski HE, Talano JA, Moskop A, Margossian SP, Verneris MR, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston M, Satwani P, Krupski C, Keating AK, Wilcox R, Rabik CA, Chinnabhandar V, Kunicki M, Goksenin AY, Mackall CL, Laetsch TW, Schultz LM, Curran KJ. PMID: 34788386; PMCID: PMC9006295.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    38. Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma. J Clin Oncol. 2022 07 01; 40(19):2106-2118. Teachey DT, Devidas M, Wood BL, Chen Z, Hayashi RJ, Hermiston ML, Annett RD, Archer JH, Asselin BL, August KJ, Cho SY, Dunsmore KP, Fisher BT, Freedman JL, Galardy PJ, Harker-Murray P, Horton TM, Jaju AI, Lam A, Messinger YH, Miles RR, Okada M, Patel SI, Schafer ES, Schechter T, Singh N, Steele AC, Sulis ML, Vargas SL, Winter SS, Wood C, Zweidler-McKay P, Bollard CM, Loh ML, Hunger SP, Raetz EA. PMID: 35271306; PMCID: PMC9242409.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCellsCTClinical Trials
    39. Decitabine and vorinostat with FLAG chemotherapy in pediatric relapsed/refractory AML: Report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium. Am J Hematol. 2022 05; 97(5):613-622. Pommert L, Schafer ES, Malvar J, Gossai N, Florendo E, Pulakanti K, Heimbruch K, Stelloh C, Chi YY, Sposto R, Rao S, Huynh VT, Brown P, Chang BH, Colace SI, Hermiston ML, Heym K, Hutchinson RJ, Kaplan JA, Mody R, O'Brien TA, Place AE, Shaw PH, Ziegler DS, Wayne A, Bhojwani D, Burke MJ. PMID: 35180323; PMCID: PMC8986610.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    40. A pilot trial of prophylactic defibrotide to prevent serious thrombotic microangiopathy in high-risk pediatric patients. Pediatr Blood Cancer. 2022 05; 69(5):e29641. Higham CS, Shimano KA, Melton A, Kharbanda S, Chu J, Dara J, Winestone LE, Hermiston ML, Huang JN, Dvorak CC. PMID: 35253361.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    41. Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium Report. Blood Adv. 2022 01 25; 6(2):600-610. Fabrizio VA, Phillips CL, Lane A, Baggott C, Prabhu S, Egeler E, Mavroukakis S, Pacenta H, Rossoff J, Stefanski HE, Talano JA, Moskop A, Margossian SP, Verneris MR, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston M, Satwani P, Krupski C, Keating AK, Wilcox R, Rabik CA, Chinnabhandar V, Kunicki M, Goksenin AY, Curran KJ, Mackall CL, Laetsch TW, Schultz LM. PMID: 34794180; PMCID: PMC8791593.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    42. Decreased IL-10 accelerates B-cell leukemia/lymphoma in a mouse model of pediatric lymphoid leukemia. Blood Adv. 2022 01 08; 6(3):854-865. Fitch BA, Zhou M, Situ J, Surianarayanan S, Reeves MQ, Hermiston ML, Wiemels JL, Wiemels JL, Kogan SC. PMID: 34727170; PMCID: PMC8945291.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimals
    43. Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report. J Clin Oncol. 2022 03 20; 40(9):945-955. Schultz LM, Baggott C, Prabhu S, Pacenta HL, Phillips CL, Rossoff J, Stefanski HE, Talano JA, Moskop A, Margossian SP, Verneris MR, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston M, Satwani P, Krupski C, Keating AK, Wilcox R, Rabik CA, Fabrizio VA, Rouce RH, Chinnabhandar V, Kunicki M, Barsan VV, Goksenin AY, Li Y, Mavroukakis S, Egeler E, Curran KJ, Mackall CL, Laetsch TW. PMID: 34882493; PMCID: PMC9384925.
      View in: PubMed   Mentions: 50     Fields:    Translation:Humans
    44. Out-of-specification tisagenlecleucel does not compromise safety or efficacy in pediatric acute lymphoblastic leukemia. Blood. 2021 11 25; 138(21):2138-2142. Rossoff J, Baggott C, Prabhu S, Pacenta H, Phillips CL, Stefanski H, Talano JA, Moskop A, Margossian SP, Verneris MR, Myers GD, Karras N, Brown PA, Qayed M, Hermiston M, Satwani P, Krupski C, Keating AK, Wilcox R, Rabik CA, Fabrizio VA, Kunicki M, Chinnabhandar V, Goksenin AY, Curran KJ, Mackall CL, Laetsch TW, Schultz LM. PMID: 34499715; PMCID: PMC8617436.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    45. Digenic Inheritance: Evidence and Gaps in Hemophagocytic Lymphohistiocytosis. Front Immunol. 2021; 12:777851. Steen EA, Hermiston ML, Nichols KE, Meyer LK. PMID: 34868048; PMCID: PMC8635482.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    46. Vincristine Sulfate Liposome Injection (VSLI, Marqibo®) in Combination with UK ALL-R3 Induction Chemotherapy for Children, Adolescents and Young Adults with Relapsed Acute Lymphoblastic Leukemia (ALL): A Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium Trial. Blood. 2021 Nov 5; 138(Supplement 1):3402-3402. Shah SN, Schafer SE, Heym HK, Place PA, Burns BM, Gossai GN, Shaw SP, Burke BM, Chang CB, Hermiston HM, Schore SR, Rushing RT, Jarosinski JP, Sposto SR, Florendo FE, Malvar MJ, Chi CY, Whitlock WJ, Silverman SL, Bhojwani BD, Wayne WA. .
      View in: Publisher Site   Mentions:
    47. Intensification of Chemotherapy Using a Modified BFM Backbone for Children, Adolescents and Young Adults with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) Identifies Highly Chemorefractory Patients Who Benefit from Allogeneic Hematopoietic Stem Cell Transplantation. Blood. 2021 Nov 5; 138(Supplement 1):3487-3487. Harker-Murray HP, Wood WB, Devidas DM, Chen CZ, Schechter-Finkelstein ST, Hayashi HR, August AK, Dunsmore DK, Hermiston HM, Horton HT, Messinger MY, Vargas VS, Schafer SE, Sulis SM, Winter WS, Wood WC, Bollard BC, Loh LM, Hunger HS, Raetz RE, Teachey TD. .
      View in: Publisher Site   Mentions:
    48. Perceptions of specialty palliative care and its role in pediatric stem cell transplant: A multidisciplinary qualitative study. Pediatr Blood Cancer. 2022 01; 69(1):e29424. Collins GS, Beaman H, Ho AM, Hermiston ML, Cohen HJ, Dzeng EW. PMID: 34705322.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    49. IFN-γ signature in the plasma proteome distinguishes pediatric hemophagocytic lymphohistiocytosis from sepsis and SIRS. Blood Adv. 2021 09 14; 5(17):3457-3467. Lin H, Scull BP, Goldberg BR, Abhyankar HA, Eckstein OE, Zinn DJ, Lubega J, Agrusa J, El Mallawaney N, Gulati N, Forbes L, Chinn I, Chakraborty R, Velasquez J, Goldman J, Bashir D, Lam F, Muscal E, Henry MM, Greenberg JN, Ladisch S, Hermiston ML, Meyer LK, Jeng M, Naqvi A, McClain K, Nguyen T, Wong H, Man TK, Jordan MB, Allen CE. PMID: 34461635; PMCID: PMC8525230.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    50. ALL-026: Evaluating Efficacy and Safety of Tisagenlecleucel Reinfusion Following Loss of B-Cell Aplasia in Pediatric and Young Adult Patients with Acute Lymphoblastic Leukemia: HESTER Phase II Study. Clinical Lymphoma Myeloma & Leukemia. 2021 Sep 1; 21:s262-s263. Boyer BM, Chaudhury CS, Davis DK, Driscoll DT, Grupp GS, Hermiston HM, John JS, Keating KA, Kovacs KC, Myers MG, Phillips PC, Pulsipher PM, Talano TJ, Kari KG, Willert WJ. .
      View in: Publisher Site   Mentions:
    51. Poster: ALL-026: Evaluating Efficacy and Safety of Tisagenlecleucel Reinfusion Following Loss of B-Cell Aplasia in Pediatric and Young Adult Patients with Acute Lymphoblastic Leukemia: HESTER Phase II Study. Clinical Lymphoma Myeloma & Leukemia. 2021 Sep 1; 21:s209. Boyer BM, Chaudhury CS, Davis DK, Driscoll DT, Grupp GS, Hermiston HM, John JS, Keating KA, Kovacs KC, Myers MG, Phillips PC, Pulsipher PM, Talano TJ, Kari KG, Willert WJ. .
      View in: Publisher Site   Mentions:
    52. Subcutaneous panniculitis-like T-cell lymphomas with homozygous inheritance of HAVCR2 mutations in Vietnamese pedigrees. Pediatr Blood Cancer. 2021 12; 68(12):e29292. Nguyen MC, Nguyen V, Le H, Nguyen DV, Nguyen ML, Hermiston ML, Bui CB, Loh AHP. PMID: 34398505.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    53. Concurrent Subcutaneous Panniculitis-like T-Cell Lymphoma and B-Cell Acute Lymphoblastic Leukemia in 2 Pediatric Patients. J Pediatr Hematol Oncol. 2021 08 01; 43(6):e791-e794. Smith GA, Levinson AL, Galvin RT, Lalor LE, McCalmont T, Wang L, Geis MC, Odegaard K, Hupp M, Maguiness S, Turcotte LM, Cordoro KM, Hermiston ML. PMID: 32852399; PMCID: PMC9433225.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    54. Targeted gene expression classifier identifies pediatric T-cell acute lymphoblastic leukemia (T-ALL) patients at high risk for end induction minimal residual disease positivity. Journal of Clinical Oncology. 2021 May 20; 39(15_suppl):10002-10002. Meyer ML, Roy RR, Huang HB, Delgado-Martin DC, Vincent VT, Wood WB, Liu LY, Zhang ZJ, Mullighan MC, Horton HT, Loh LM, Devidas DM, Raetz RE, Hayashi HR, Winter WS, Dunsmore DK, Hunger HS, Teachey TD, Olshen OA, Hermiston HM. .
      View in: Publisher Site   Mentions:
    55. Fludarabine-exposure predicts disease control following CD19-specific car t cell (tisagenlecleucel); a report from pediatric real-world car consortium. Cytotherapy. 2021 May 1; 23(5):s27. Curran CK, Fabrizio FV, Mauguen MA, Boelens BJ, Baggott BC, Prabhu PS, Placenta PH, Phillips PC, Rossoff RJ, Stefanski SH, Talano TJ, Moskop MA, Margossian MS, Verneris VM, Myers MG, Karras KN, Brown BP, Qayed QM, Hermiston HM, Satwani SP, Krupski KC, Keating KA, Wilcox WR, Rabik RC, Chinnabhandar CV, Kunicki KM, Goksenin GA, Mackall MC, Laetsch LT, Schultz SL. .
      View in: Publisher Site   Mentions:
    56. T-cell activation profiles distinguish hemophagocytic lymphohistiocytosis and early sepsis. Blood. 2021 04 29; 137(17):2337-2346. Chaturvedi V, Marsh RA, Zoref-Lorenz A, Owsley E, Chaturvedi V, Nguyen TC, Goldman JR, Henry MM, Greenberg JN, Ladisch S, Hermiston ML, Jeng M, Naqvi A, Allen CE, Wong HR, Jordan MB. PMID: 33512385; PMCID: PMC8085480.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansCells
    57. Double trouble for Langerhans cell histiocytosis. Blood. 2021 04 01; 137(13):1705-1706. Hermiston ML. PMID: 33792676.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    58. 149 Evaluating Efficacy and Safety of Tisagenlecleucel Reinfusion Following Loss of B-Cell Aplasia in Pediatric and Young Adult Patients with Acute Lymphoblastic Leukemia: HESTER Phase II Study. . 2021 Mar 1; 27(3):s141-s142. Boyer BM, Chaudhury CS, Davis DK, Driscoll DT, Grupp GS, Hermiston HM, John JS, Keating KA, Kovacs KC, Magley MA, Myers MG, Phillips PC, Pulsipher PM, Purkayastha PD, Talano TJ, Adisa AO, Willert WJ. .
      View in: Publisher Site   Mentions:
    59. HESTER: A Phase II Study Evaluating Efficacy and Safety of Tisagenlecleucel Reinfusion in Pediatric and Young Adult Patients with Acute Lymphoblastic Leukemia Experiencing Loss of B-Cell Aplasia. Blood. 2020 Nov 5; 136(Supplement 1):23-24. Boyer BM, Chaudhury CS, Davis DK, Driscoll DT, Grupp GS, Hermiston HM, John JS, Keating KA, Kovacs KC, Magley MA, Myers MG, Phillips PC, Pulsipher PM, Purkayastha PD, Talano TJ, Willert WJ. .
      View in: Publisher Site   Mentions:
    60. ZUMA-4: A Phase 1/2 Multicenter Study of KTE-X19 in Pediatric and Adolescent Patients With Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma. Blood. 2020 Nov 5; 136(Supplement 1):42-42. Wayne WA, Michel MG, Lee LD, Baruchel BA, Chaudhury CS, Brown BP, Hermiston HM, Krueger KJ, Shen ST, Tailford TK, Masouleh MB. .
      View in: Publisher Site   Mentions:
    61. Cranial Radiation Can be Eliminated in Most Children with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Bortezomib Potentially Improves Survival in Children with T-Cell Lymphoblastic Lymphoma (T-LL): Results of Children's Oncology Group (COG) Trial AALL1231. Blood. 2020 Nov 5; 136(Supplement 1):11-12. Teachey TD, Devidas DM, Wood WB, Chen CZ, Hayashi HR, Annett AR, Asselin AB, August AK, Cho CS, Dunsmore DK, Fisher FB, Freedman FJ, Galardy GP, Harker-Murray HP, Hermiston HM, Horton HT, Jaju JA, Lam LA, Messinger MY, Miles MR, Okada OM, Patel PS, Schafer SE, Schechter-Finkelstein ST, Shimano SK, Singh SN, Steele SA, Sulis SM, Vargas VS, Winter WS, Wood WC, McKay MP, Bollard BC, Loh LM, Hunger HS, Raetz RE. .
      View in: Publisher Site   Mentions:
    62. JAK/STAT pathway inhibition sensitizes CD8 T cells to dexamethasone-induced apoptosis in hyperinflammation. Blood. 2020 08 06; 136(6):657-668. Meyer LK, Verbist KC, Albeituni S, Scull BP, Bassett RC, Stroh AN, Tillman H, Allen CE, Hermiston ML, Nichols KE. PMID: 32530039; PMCID: PMC7414590.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansAnimalsCells
    63. Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Children's Oncology Group AALL0434. J Clin Oncol. 2020 09 10; 38(26):3062-3070. Hayashi RJ, Winter SS, Dunsmore KP, Devidas M, Chen Z, Wood BL, Hermiston ML, Teachey DT, Perkins SL, Miles RR, Raetz EA, Loh ML, Winick NJ, Carroll WL, Hunger SP, Lim MS, Gross TG, Bollard CM. PMID: 32552472; PMCID: PMC7479761.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCTClinical Trials
    64. Glucocorticoids paradoxically facilitate steroid resistance in T cell acute lymphoblastic leukemias and thymocytes. J Clin Invest. 2020 02 03; 130(2):863-876. Meyer LK, Huang BJ, Delgado-Martin C, Roy RP, Hechmer A, Wandler AM, Vincent TL, Fortina P, Olshen AB, Wood BL, Horton TM, Shannon KM, Teachey DT, Hermiston ML. PMID: 31687977; PMCID: PMC6994137.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansAnimalsCells
    65. Decitabine and Vorinostat with Chemotherapy in Relapsed Pediatric Acute Lymphoblastic Leukemia: A TACL Pilot Study. Clin Cancer Res. 2020 05 15; 26(10):2297-2307. Burke MJ, Kostadinov R, Sposto R, Gore L, Kelley SM, Rabik C, Trepel JB, Lee MJ, Yuno A, Lee S, Bhojwani D, Jeha S, Chang BH, Sulis ML, Hermiston ML, Gaynon P, Huynh V, Verma A, Gardner R, Heym KM, Dennis RM, Ziegler DS, Laetsch TW, Oesterheld JE, Dubois SG, Pollard JA, Glade-Bender J, Cooper TM, Kaplan JA, Farooqi MS, Yoo B, Guest E, Wayne AS, Brown PA. PMID: 31969338; PMCID: PMC7477726.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    66. The bone marrow microenvironment as a mediator of chemoresistance in acute lymphoblastic leukemia. Cancer Drug Resist. 2019; 2(4):1164-1177. Meyer LK, Hermiston ML. PMID: 35582273; PMCID: PMC9019215.
      View in: PubMed   Mentions: 5  
    67. The Combination of Dexamethasone and Ruxolitinib Synergistically Attenuates Disease Manifestations in a Preclinical Model of Hemophagocytic Lymphohistiocytosis. Blood. 2019 Nov 13; 134(Supplement_1):81-81. Meyer ML, Verbist VK, Albeituni AS, Bassett BR, Hermiston HM, Nichols NK. .
      View in: Publisher Site   Mentions:
    68. Protein Translocation Inhibitors Overcome Cytokine-Induced Glucocorticoid Resistance in T-Cell Acute Lymphoblastic Leukemia. Blood. 2019 Nov 13; 134(Supplement_1):805-805. Meyer ML, Delgado-Martin DC, Sharp SP, McMinn MD, Kirk KC, Taunton TJ, Hermiston HM. .
      View in: Publisher Site   Mentions:
    69. Role of Disease Mechanism in Hematopoietic Cell Transplantation Outcomes for Hemophagocytic Lymphohistiocytosis. Blood. 2019 Nov 13; 134(Supplement_1):3343-3343. Dain DA, Hermiston HM, Shimano SK, Kharbanda KS, Melton MA, Dara DJ, Huang HJ, Dvorak DC. .
      View in: Publisher Site   Mentions:
    70. Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: Recommendations from the North American Consortium for Histiocytosis (NACHO). Pediatr Blood Cancer. 2019 11; 66(11):e27929. Jordan MB, Allen CE, Greenberg J, Henry M, Hermiston ML, Kumar A, Hines M, Eckstein O, Ladisch S, Nichols KE, Rodriguez-Galindo C, Wistinghausen B, McClain KL. PMID: 31339233; PMCID: PMC7340087.
      View in: PubMed   Mentions: 108     Fields:    Translation:Humans
    71. CRLF2 rearrangement in Ph-like acute lymphoblastic leukemia predicts relative glucocorticoid resistance that is overcome with MEK or Akt inhibition. PLoS One. 2019; 14(7):e0220026. Meyer LK, Delgado-Martin C, Maude SL, Shannon KM, Teachey DT, Hermiston ML. PMID: 31318944; PMCID: PMC6638974.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    72. Calming the storm in HLH. Blood. 2019 07 11; 134(2):103-104. Zinter MS, Hermiston ML. PMID: 31296541.
      View in: PubMed   Mentions: 12     Fields:    Translation:Animals
    73. The epigenome in pediatric acute lymphoblastic leukemia: drug resistance and therapeutic opportunities. Cancer Drug Resist. 2019; 2(2):313-325. Meyer LK, Hermiston ML. PMID: 35582725; PMCID: PMC8992636.
      View in: PubMed   Mentions: 4  
    74. PS962 PHASE 1 RESULTS OF ZUMA-4: KTE-X19, AN ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY, IN PEDIATRIC AND ADOLESCENT PATIENTS WITH RELAPSED/REFRACTORY B CELL ACUTE LYMPHOBLASTIC LEUKEMIA. HemaSphere. 2019 Jun 1; 3(S1):433. Wayne WA, Huynh HV, Hijiya HN, Rouce RR, Brown BP, Krueger KJ, Rytting RM, Kitko KC, Dela Ziga DE, Hermiston HM, Richards RM, Baruchel BA, Shen ST, Goyal GL, Vezan VR, Jain JR, Lee LD. .
      View in: Publisher Site   Mentions:
    75. Gene expression signature associated with in vitro dexamethasone resistance and post-induction minimal residual disease in pediatric T-cell acute lymphoblastic leukemia. Journal of Clinical Oncology. 2019 May 20; 37(15_suppl):10033-10033. Meyer ML, Delgado-Martin DC, Roy RR, Huang HB, Vincent VT, Olshen OA, Wood WB, Liu LY, Zhang ZJ, Mullighan MC, Horton HT, Loh LM, Devidas DM, Raetz RE, Hayashi HR, Winter WS, Dunsmore DK, Hunger HS, Teachey TD, Hermiston HM. .
      View in: Publisher Site   Mentions:
    76. Lymphoblastic lymphoma in children and adolescents: review of current challenges and future opportunities. Br J Haematol. 2019 06; 185(6):1158-1170. Burkhardt B, Hermiston ML. PMID: 30809797.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    77. Mechanisms of Glucocorticoid Response and Resistance in Lymphoid Malignancies. . 2019 Jan 1; 21:1-26. Meyer ML, Hermiston HM. .
      View in: Publisher Site   Mentions:
    78. Children's Oncology Group (COG) AALL0434: Successful Disease Control without Cranial Radiation in Newly Diagnosed T Lymphoblastic Lymphoma (T-LL). Blood. 2018 Nov 29; 132(Supplement 1):1000-1000. Hayashi HR, Winter WS, Dunsmore DK, Devidas DM, Wood WB, Hermiston HM, Teachey TD, Perkins PS, Miles MR, Raetz RE, Loh LM, Winick WN, Carroll CW, Hunger HS, Lim LM, Bollard BC, Gross GT. .
      View in: Publisher Site   Mentions:
    79. Glucocorticoids Paradoxically Induce Intrinsic Steroid Resistance through a STAT5-Mediated Survival Mechanism in T-Cell Acute Lymphoblastic Leukemia. Blood. 2018 Nov 29; 132(Supplement 1):913-913. Meyer ML, Huang HB, Roy RR, Hechmer HA, Wandler WA, Delgado-Martin DC, Olshen OA, Horton HT, Teachey TD, Shannon SK, Hermiston HM. .
      View in: Publisher Site   Mentions:
    80. Ibrutinib significantly inhibited Bruton's tyrosine kinase (BTK) phosphorylation,in-vitro proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) model. Oncoimmunology. 2019; 8(1):e1512455. Chu Y, Lee S, Shah T, Yin C, Barth M, Miles RR, Ayello J, Morris E, Harrison L, Van de Ven C, Galardy P, Goldman SC, Lim MS, Hermiston M, McAllister-Lucas LM, Giulino-Roth L, Perkins SL, Cairo MS. PMID: 30546948; PMCID: PMC6287791.
      View in: PubMed   Mentions: 14     Fields:    
    81. Age-Related Impaired Efficacy of Bone Marrow Cell Therapy for Myocardial Infarction Reflects a Decrease in B Lymphocytes. Mol Ther. 2018 07 05; 26(7):1685-1693. An S, Wang X, Ruck MA, Rodriguez HJ, Kostyushev DS, Varga M, Luu E, Derakhshandeh R, Suchkov SV, Kogan SC, Hermiston ML, Springer ML. PMID: 29914756; PMCID: PMC6036225.
      View in: PubMed   Mentions: 6     Fields:    Translation:AnimalsCells
    82. High-Throughput Flow Cytometry Identifies Small-Molecule Inhibitors for Drug Repurposing in T-ALL. SLAS Discov. 2018 08; 23(7):732-741. Perez DR, Nickl CK, Waller A, Delgado-Martin C, Woods T, Sharma ND, Hermiston ML, Loh ML, Hunger SP, Winter SS, Chigaev A, Edwards B, Sklar LA, Matlawska-Wasowska K. PMID: 29746793; PMCID: PMC6292518.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    83. Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study. Leukemia. 2018 11; 32(11):2316-2325. Sun W, Malvar J, Sposto R, Verma A, Wilkes JJ, Dennis R, Heym K, Laetsch TW, Widener M, Rheingold SR, Oesterheld J, Hijiya N, Sulis ML, Huynh V, Place AE, Bittencourt H, Hutchinson R, Messinger Y, Chang B, Matloub Y, Ziegler DS, Gardner R, Cooper T, Ceppi F, Hermiston M, Dalla-Pozza L, Schultz KR, Gaynon P, Wayne AS, Whitlock JA. PMID: 29728694; PMCID: PMC6224404.
      View in: PubMed   Mentions: 51     Fields:    Translation:HumansCells
    84. Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia. Blood. 2018 03 01; 131(9):995-999. Bride KL, Vincent TL, Im SY, Aplenc R, Barrett DM, Carroll WL, Carson R, Dai Y, Devidas M, Dunsmore KP, Fuller T, Glisovic-Aplenc T, Horton TM, Hunger SP, Loh ML, Maude SL, Raetz EA, Winter SS, Grupp SA, Hermiston ML, Wood BL, Teachey DT. PMID: 29305553; PMCID: PMC5833263.
      View in: PubMed   Mentions: 75     Fields:    Translation:HumansAnimals
    85. Evaluation and treatment of Langerhans cell histiocytosis patients with central nervous system abnormalities: Current views and new vistas. Pediatr Blood Cancer. 2018 Jan; 65(1). Yeh EA, Greenberg J, Abla O, Longoni G, Diamond E, Hermiston M, Tran B, Rodriguez-Galindo C, Allen CE, McClain KL, North American Consortium for Histiocytosis. PMID: 28944988.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    86. Abstract 2642: Preclinical efficacy of daratumumab in acute lymphoblastic leukemia. Clinical Research (Excluding Clinical Trials). 2017 Jul 1; 2642-2642. Bride BK, Vincent VT, Im IS, Fuller FT, Ryan RT, Barrett BD, Maude MS, Loh LM, Hermiston HM, Grupp GS, Wood WB, Teachey TD. .
      View in: Publisher Site   Mentions:
    87. Manipulating DNA damage-response signaling for the treatment of immune-mediated diseases. Proc Natl Acad Sci U S A. 2017 06 13; 114(24):E4782-E4791. McNally JP, Millen SH, Chaturvedi V, Lakes N, Terrell CE, Elfers EE, Carroll KR, Hogan SP, Andreassen PR, Kanter J, Allen CE, Henry MM, Greenberg JN, Ladisch S, Hermiston ML, Joyce M, Hildeman DA, Katz JD, Jordan MB. PMID: 28533414; PMCID: PMC5474825.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansAnimalsCells
    88. JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias. Leukemia. 2017 12; 31(12):2568-2576. Delgado-Martin C, Meyer LK, Huang BJ, Shimano KA, Zinter MS, Nguyen JV, Smith GA, Taunton J, Winter SS, Roderick JR, Kelliher MA, Horton TM, Wood BL, Teachey DT, Hermiston ML. PMID: 28484265; PMCID: PMC5729333.
      View in: PubMed   Mentions: 60     Fields:    Translation:HumansAnimalsCells
    89. Measurement of Phosphorylated ERK As a Prognostic and Predictive Marker for MEK Inhibition in Pediatric B-Lymphoblastic Leukemia: A Pilot Study. Blood. 2016 Dec 2; 128(22):1739-1739. Madhusoodhan MP, Evensen EN, Saliba SJ, Chowdhury CA, Newman ND, Delgado-Martin DC, Bhatla BT, Loh LM, Hermiston HM, Carroll CW. .
      View in: Publisher Site   Mentions:
    90. JAK/STAT Pathway Inhibition Reverts IL7-Induced Glucocorticoid Resistance in a Subset of Human T-Cell Acute Lymphoblastic Leukemia. Blood. 2016 Dec 2; 128(22):3963-3963. Delgado-Martin DC, Shimano SK, Zinter ZM, Wahlstrom WJ, Smith SG, Taunton TJ, Winter WS, Roderick RJ, Kelliher KM, Horton HT, Wood WB, Teachey TD, Hermiston HM. .
      View in: Publisher Site   Mentions:
    91. Microrna (miR)-17-92 Contributes to Therapy Resistance in Burkitt Lymphoma Cells. Blood. 2016 Dec 2; 128(22):2944-2944. Miles MR, Rodic RV, Barth BM, Cairo CM, Hermiston HM. .
      View in: Publisher Site   Mentions:
    92. CRLF2 Rearrangement Status in Ph-like ALL Predicts Intrinsic Glucocorticoid Resistance In Vitro that is Reversible with Targeted MAPK and PI3K Pathway Inhibition. Blood. 2016 Dec 2; 128(22):910-910. Meyer ML, Delgado-Martin DC, Maude MS, Teachey TD, Hermiston HM. .
      View in: Publisher Site   Mentions:
    93. Mechanism of IL-10 Protective Effect in Development of Childhood B Cell Acute Lymphoblastic Leukemia. Blood. 2016 Dec 2; 128(22):4075-4075. Fitch FB, Hermiston HM, Wiemels WJ, Kogan KS. .
      View in: Publisher Site   Mentions:
    94. Targeting childhood, adolescent and young adult non-Hodgkin lymphoma: therapeutic horizons. Br J Haematol. 2016 05; 173(4):625-36. Galardy PJ, Bedekovics T, Hermiston ML. PMID: 27019108.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    95. Ibrutinib Alone and in Combination with Dexamethasone and Carfilzomib Significantly Inhibits Cell Proliferation in Primary Mediastinal B-Cell Lymphoma (PMBL): Ibrutinib May be a Future Targeted Agent in Combination Therapy in Patients with PMBL. Blood. 2015 Dec 3; 126(23):4852-4852. Lee LS, Yin YC, Ayello AJ, Morris ME, Harrison HL, van de Ven vC, Barth BM, Miles MR, Galardy GP, Goldman GS, Lim LM, Hermiston HM, McAllister-Lucas ML, Giulino-Roth GL, Perkins PS, Cairo CM. .
      View in: Publisher Site   Mentions:
    96. Ibrutinib Significantly Prolonged Survival in a Human Burkitt Lymphoma (BL) Xenograft NSG Mouse Model: Ibrutinib May be a Potential Adjuvant Agent in the Treatment of BL. Blood. 2015 Dec 3; 126(23):5117-5117. Lee LS, Yin YC, Ayello AJ, Morris ME, O'Connell OT, Harrison HL, van de Ven vC, Barth BM, Miles MR, Galardy GP, Goldman GS, Lim LM, Hermiston HM, McAllister-Lucas ML, Giulino-Roth GL, Perkins PS, Cairo CM. .
      View in: Publisher Site   Mentions:
    97. Abstract 17412: Paracrine Role of B Lymphocytes in Successful Bone Marrow Cell Therapy for Myocardial Infarction. Circulation. 2015 Nov 10; 132(suppl_3). Wang WX, Rodriguez RH, Ruck RM, Aschbacher AK, Hermiston HM, Springer SM. .
      View in: Publisher Site   Mentions:
    98. MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia. Blood. 2015 Nov 05; 126(19):2202-12. Jones CL, Gearheart CM, Fosmire S, Delgado-Martin C, Evensen NA, Bride K, Waanders AJ, Pais F, Wang J, Bhatla T, Bitterman DS, de Rijk SR, Bourgeois W, Dandekar S, Park E, Burleson TM, Madhusoodhan PP, Teachey DT, Raetz EA, Hermiston ML, Müschen M, Loh ML, Hunger SP, Zhang J, Garabedian MJ, Porter CC, Carroll WL. PMID: 26324703; PMCID: PMC4635116.
      View in: PubMed   Mentions: 55     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    99. Unbiased modifier screen reveals that signal strength determines the regulatory role murine TLR9 plays in autoantibody production. J Immunol. 2015 Apr 15; 194(8):3675-86. Mills RE, Lam VC, Tan A, Cresalia N, Oksenberg N, Zikherman J, Anderson M, Weiss A, Hermiston ML. PMID: 25769918; PMCID: PMC4503364.
      View in: PubMed   Mentions: 7     Fields:    Translation:AnimalsCells
    100. Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia. Blood. 2015 Mar 12; 125(11):1759-67. Maude SL, Dolai S, Delgado-Martin C, Vincent T, Robbins A, Selvanathan A, Ryan T, Hall J, Wood AC, Tasian SK, Hunger SP, Loh ML, Mullighan CG, Wood BL, Hermiston ML, Grupp SA, Lock RB, Teachey DT. PMID: 25645356; PMCID: PMC4357583.
      View in: PubMed   Mentions: 120     Fields:    Translation:HumansAnimalsCells
    101. MAPK Signaling Cascades Mediate Distinct Glucocorticoid Resistance Mechanisms in Pediatric B-Precursor ALL. Blood. 2014 Dec 6; 124(21):789-789. Jones JC, Gearheart GC, Fosmire FS, Delgado-Martin DC, Pais PF, Wang WJ, Bhatla BT, Bitterman BD, de Rijk dS, Bourgeois BW, Dandekar DS, Raetz RE, Hermiston HM, Garabedian GM, Porter PC, Carroll CW. .
      View in: Publisher Site   Mentions:
    102. The CXCR4/CXCL12 Axis Mediates Chemotaxis, Survival, and Chemoresistance in T-Cell Acute Lymphoblastic Leukemia. Blood. 2014 Dec 6; 124(21):3629-3629. Liou LA, Delgado-Martin DC, Teachey TD, Hermiston HM. .
      View in: Publisher Site   Mentions:
    103. Wnt inhibition leads to improved chemosensitivity in paediatric acute lymphoblastic leukaemia. Br J Haematol. 2014 Oct; 167(1):87-99. Dandekar S, Romanos-Sirakis E, Pais F, Bhatla T, Jones C, Bourgeois W, Hunger SP, Raetz EA, Hermiston ML, Dasgupta R, Morrison DJ, Carroll WL. PMID: 24995804; PMCID: PMC4207443.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansCells
    104. A(nother) RAF mutation in LCH. Blood. 2014 May 15; 123(20):3063-5. Shannon K, Hermiston M. PMID: 24832939; PMCID: PMC4023415.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimals
    105. Inhibition Of The Wnt Pathway Leads To Improved Chemosensitivity In Pediatric Acute Lymphoblastic Leukemia. Blood. 2013 Nov 15; 122(21):1428-1428. Dandekar DS, Romanos-Sirakis RE, Pais PF, Bhatla BT, Jones JC, Bourgeois BW, Hunger HS, Raetz RE, Hermiston HM, Dasgupta DR, Morrison MD, Carroll CW. .
      View in: Publisher Site   Mentions:
    106. Transcription Activator-Like Effector Nucleases (TALENs)-Mediated Deletion Of MIR17HG In Burkitt Lymphoma Cells Decreases mTOR Pathway Activity and Increases Chemosensitivity. Blood. 2013 Nov 15; 122(21):243-243. Pais PF, Lee LS, Rodic RV, Barth BM, Cairo CM, Hermiston HM, Miles MR. .
      View in: Publisher Site   Mentions:
    107. Histone Deacetylase Inhibitors Enhance Cell Death In Burkitt Lymphoma Cells By Modulating Expression Of The WNT/ß-Catenin Pathway and Survivin. Blood. 2013 Nov 15; 122(21):1291-1291. Pais PF, Barth BM, Miles MR, Hermiston HM. .
      View in: Publisher Site   Mentions:
    108. The structural wedge domain of the receptor-like tyrosine phosphatase CD45 enforces B cell tolerance by regulating substrate specificity. J Immunol. 2013 Mar 15; 190(6):2527-35. Zikherman J, Parameswaran R, Hermiston M, Weiss A. PMID: 23396948; PMCID: PMC3593789.
      View in: PubMed   Mentions: 7     Fields:    Translation:AnimalsCells
    109. Initially disadvantaged, TEL-AML1 cells expand and initiate leukemia in response to irradiation and cooperating mutations. Leukemia. 2013 Jul; 27(7):1570-3. Li M, Jones L, Gaillard C, Binnewies M, Ochoa R, Garcia E, Lam V, Wei G, Yang W, Lobe C, Hermiston M, Passegué E, Kogan SC. PMID: 23443342; PMCID: PMC3715751.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansAnimalsCells
    110. The Order of Exposure to Cytotoxic Chemotherapy and the Proteasome Inhibitor Bortezomib Dictates the Extent of Reversal of Chemotherapy Resistance in T-ALL. Blood. 2012 Nov 16; 120(21):1355-1355. Szeto SM, Wahlstrom WJ, Hermiston HM. .
      View in: Publisher Site   Mentions:
    111. Cellular and molecular mechanisms for lupus nephritis in a mouse model of systemic lupus erythematosus (159.4). The Journal of Immunology. 2012 May 1; 188(1_Supplement):159.4-159.4. Hai HS, Lam LV, Cook CB, Hermiston HM. .
      View in: Publisher Site   Mentions:
    112. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature. 2012 Jan 11; 481(7380):157-63. Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, Payne-Turner D, Easton J, Chen X, Wang J, Rusch M, Lu C, Chen SC, Wei L, Collins-Underwood JR, Ma J, Roberts KG, Pounds SB, Ulyanov A, Becksfort J, Gupta P, Huether R, Kriwacki RW, Parker M, McGoldrick DJ, Zhao D, Alford D, Espy S, Bobba KC, Song G, Pei D, Cheng C, Roberts S, Barbato MI, Campana D, Coustan-Smith E, Shurtleff SA, Raimondi SC, Kleppe M, Cools J, Shimano KA, Hermiston ML, Doulatov S, Eppert K, Laurenti E, Notta F, Dick JE, Basso G, Hunger SP, Loh ML, Devidas M, Wood B, Winter S, Dunsmore KP, Fulton RS, Fulton LL, Hong X, Harris CC, Dooling DJ, Ochoa K, Johnson KJ, Obenauer JC, Evans WE, Pui CH, Naeve CW, Ley TJ, Mardis ER, Wilson RK, Downing JR, Mullighan CG. PMID: 22237106; PMCID: PMC3267575.
      View in: PubMed   Mentions: 849     Fields:    Translation:HumansCells
    113. Aberrant MAPK and PI3K Signaling Contribute to Chemotherapy Resistance in T Cell Acute Lymphoblastic Leukemia by Altering the Balance of Apoptosis Mediators,. Blood. 2011 Nov 18; 118(21):3490-3490. Wahlstrom WJ, Ammon AK, Esquivel EC, Law LJ, Hermiston HM. .
      View in: Publisher Site   Mentions:
    114. Discovery of Novel Recurrent Mutations in Childhood Early T-Cell Precursor Acute Lymphoblastic Leukemia by Whole Genome Sequencing - a Report From the St Jude Children's Research Hospital - Washington University Pediatric Cancer Genome Project. Blood. 2011 Nov 18; 118(21):68-68. Zhang ZJ, Ding DL, Holmfeldt HL, Wu WG, Heatley HS, Payne-Turner PD, Easton EJ, Chen CX, Wang WJ, Rusch RM, Lu LC, Chen CS, Collins-Underwood CR, Ma MJ, Roberts RK, Pounds PS, Wei WL, Ulyanov UA, Becksfort BJ, Gupta GP, Huether HR, Kriwacki KR, McGoldrick MD, Zhao ZD, Alford AD, Espy ES, Bobba BK, Song SG, Pei PD, Cheng CC, Roberts RS, Barbato BM, Campana CD, Coustan-Smith CE, Evans EW, Shurtleff SS, Kleppe KM, Cools CJ, Shimano SK, Hermiston HM, Doulatov DS, Eppert EK, Laurenti LE, Notta NF, Dick DJ, Basso BG, Hunger HS, Loh LM, Devidas DM, Wood WB, Winter WS, Dunsmore DK, Fulton FR, Fulton FL, Hong HX, Harris HC, Dooling DD, Ochoa OK, Johnson JK, Obenauer OJ, Pui PC, Raimondi RS, Naeve NC, Ley LT, Mardis ME, Wilson WR, Downing DJ, Mullighan MC. .
      View in: Publisher Site   Mentions:
    115. Donor myocardial infarction impairs the therapeutic potential of bone marrow cells by an interleukin-1-mediated inflammatory response. Sci Transl Med. 2011 Sep 14; 3(100):100ra90. Wang X, Takagawa J, Lam VC, Haddad DJ, Tobler DL, Mok PY, Zhang Y, Clifford BT, Pinnamaneni K, Saini SA, Su R, Bartel MJ, Sievers RE, Carbone L, Kogan S, Yeghiazarians Y, Hermiston M, Springer ML. PMID: 21918107; PMCID: PMC3350804.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansAnimals
    116. An activating mutation in CD45 generates a novel murine model of hemophagocytic disorders in the context of a MHC Class 1 restricted TCR. (109.11). The Journal of Immunology. 2011 Apr 1; 186(1_Supplement):109.11-109.11. Tibbetts TR, Lam LV, Cresalia CN, DeGraaf DF, Goren GN, Wong WL, Hai HS, Mills MR, Roque RA, Arthur AW, Hermiston HM. .
      View in: Publisher Site   Mentions:
    117. Impact of TLR9 on hyper-responsive ITAM signaling in a mouse model of SLE (47.24). The Journal of Immunology. 2011 Apr 1; 186(1_Supplement):47.24-47.24. Mills MR, Lam LV, Tobler TD, Oksenberg ON, Cresalia CN, Anderson AM, Mao MJ, Weiss WA, Hermiston HM. .
      View in: Publisher Site   Mentions:
    118. Chapter 95 CD45. Handbook of Cell Signaling. 2010 Jan 1; 743-748. Hermiston HM, Gupta GV, Weiss WA. .
      View in: Publisher Site   Mentions:
    119. Distinct Signaling Profiles and Drug Responses Identify Subpopulations of Pediatric T-Cell Acute Lymphoblastic Leukemia and Lymphoma Patients. Blood. 2009 Nov 20; 114(22):1595-1595. Law LJ, Ammon AK, Zinter ZM, Wen WJ, Cook CB, Irish IJ, Hermiston HM. .
      View in: Publisher Site   Mentions:
    120. PTPN22 deficiency cooperates with the CD45 E613R allele to break tolerance on a non-autoimmune background. J Immunol. 2009 Apr 01; 182(7):4093-106. Zikherman J, Hermiston M, Steiner D, Hasegawa K, Chan A, Weiss A. PMID: 19299707; PMCID: PMC2765978.
      View in: PubMed   Mentions: 81     Fields:    Translation:HumansAnimalsCells
    121. Requirement for CD45 in fine-tuning mast cell responses mediated by different ligand-receptor systems. Cell Signal. 2009 Aug; 21(8):1277-86. Grochowy G, Hermiston ML, Kuhny M, Weiss A, Huber M. PMID: 19332117.
      View in: PubMed   Mentions: 9     Fields:    Translation:AnimalsCells
    122. Oncogenic Kras initiates leukemia in hematopoietic stem cells. PLoS Biol. 2009 Mar 17; 7(3):e59. Sabnis AJ, Cheung LS, Dail M, Kang HC, Santaguida M, Hermiston ML, Passegué E, Shannon K, Braun BS. PMID: 19296721; PMCID: PMC2656550.
      View in: PubMed   Mentions: 55     Fields:    Translation:AnimalsCells
    123. CD45, CD148, and Lyp/Pep: critical phosphatases regulating Src family kinase signaling networks in immune cells. Immunol Rev. 2009 Mar; 228(1):288-311. Hermiston ML, Zikherman J, Zhu JW. PMID: 19290935; PMCID: PMC2739744.
      View in: PubMed   Mentions: 79     Fields:    Translation:HumansAnimalsCells
    124. Differential impact of the CD45 juxtamembrane wedge on central and peripheral T cell receptor responses. Proc Natl Acad Sci U S A. 2009 Jan 13; 106(2):546-51. Hermiston ML, Zikherman J, Tan AL, Lam VC, Cresalia NM, Oksenberg N, Goren N, Brassat D, Oksenberg JR, Weiss A. PMID: 19129486; PMCID: PMC2626740.
      View in: PubMed   Mentions: 10     Fields:    Translation:AnimalsCells
    125. B cells drive lymphocyte activation and expansion in mice with the CD45 wedge mutation and Fas deficiency. J Exp Med. 2008 Nov 24; 205(12):2755-61. Gupta VA, Hermiston ML, Cassafer G, Daikh DI, Weiss A. PMID: 19001138; PMCID: PMC2585841.
      View in: PubMed   Mentions: 8     Fields:    Translation:AnimalsCells
    126. Langerhans' Cell Histiocytosis. Clinical Endocrine Oncology. 2008 Apr 15; 325-330. Gorman GM, Hermiston HM, Matthay MK. .
      View in: Publisher Site   Mentions:
    127. A Point Mutation in the Juxtamembrane Wedge of CD45 Impacts Myeloid Development and Generates a Novel Model for Hemophagocytic Disorders in the Context of a MHC I-Restricted Transgene. Blood. 2007 Nov 16; 110(11):317-317. Hermiston HM, de Graaf dF, Weiss WA. .
      View in: Publisher Site   Mentions:
    128. The Phenotypic Consequences of an Activating Mutation in the Juxtamembrane Wedge of CD45 Is Sensitive to Genetic Modifiers. Blood. 2006 Nov 16; 108(11):1730-1730. Hermiston HM, Cresalia CN, Lam LV, Tan TA, Weiss WA. .
      View in: Publisher Site   Mentions:
    129. Epstein-Barr virus-associated B cell lymphoproliferative disease in a child with neonatal-onset multisystem inflammatory disease. Arthritis Rheum. 2006 Oct 15; 55(5):823-5. Modica R, Emery H, Lam W, Hermiston M, Grenert J, Wirt M, von Scheven E. PMID: 17013844.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    130. Dysregulation of signaling pathways in CD45-deficient NK cells leads to differentially regulated cytotoxicity and cytokine production. Proc Natl Acad Sci U S A. 2006 May 02; 103(18):7012-7. Hesslein DG, Takaki R, Hermiston ML, Weiss A, Lanier LL. PMID: 16627620; PMCID: PMC1459010.
      View in: PubMed   Mentions: 34     Fields:    Translation:AnimalsCells
    131. The juxtamembrane wedge negatively regulates CD45 function in B cells. Immunity. 2005 Dec; 23(6):635-47. Hermiston ML, Tan AL, Gupta VA, Majeti R, Weiss A. PMID: 16356861.
      View in: PubMed   Mentions: 26     Fields:    Translation:AnimalsCells
    132. Chapter 114 CD45. Handbook of Cell Signaling. 2003 Jan 1; (Annu. Rev. Immunol.121994):689-691. Xu XZ, Hermiston HM, Weiss WA. .
      View in: Publisher Site   Mentions:
    133. Reciprocal regulation of lymphocyte activation by tyrosine kinases and phosphatases. J Clin Invest. 2002 Jan; 109(1):9-14. Hermiston ML, Xu Z, Majeti R, Weiss A. PMID: 11781344; PMCID: PMC150828.
      View in: PubMed   Mentions: 55     Fields:    Translation:HumansAnimalsCells
    134. Phenotype of mice lacking functional Deleted in colorectal cancer (Dcc) gene. Nature. 1997 Apr 24; 386(6627):796-804. Fazeli A, Dickinson SL, Hermiston ML, Tighe RV, Steen RG, Small CG, Stoeckli ET, Keino-Masu K, Masu M, Rayburn H, Simons J, Bronson RT, Gordon JI, Tessier-Lavigne M, Weinberg RA. PMID: 9126737.
      View in: PubMed   Mentions: 261     Fields:    Translation:HumansAnimalsCells
    135. Forced expression of the tumor suppressor adenomatosis polyposis coli protein induces disordered cell migration in the intestinal epithelium. Proc Natl Acad Sci U S A. 1996 Sep 03; 93(18):9588-93. Wong MH, Hermiston ML, Syder AJ, Gordon JI. PMID: 8790374; PMCID: PMC38472.
      View in: PubMed   Mentions: 58     Fields:    Translation:HumansAnimalsCells
    136. Forced expression of E-cadherin in the mouse intestinal epithelium slows cell migration and provides evidence for nonautonomous regulation of cell fate in a self-renewing system. Genes Dev. 1996 Apr 15; 10(8):985-96. Hermiston ML, Wong MH, Gordon JI. PMID: 8608945.
      View in: PubMed   Mentions: 71     Fields:    Translation:Animals
    137. Inflammatory bowel disease and adenomas in mice expressing a dominant negative N-cadherin. Science. 1995 Nov 17; 270(5239):1203-7. Hermiston ML, Gordon JI. PMID: 7502046.
      View in: PubMed   Mentions: 169     Fields:    Translation:AnimalsCells
    138. Organization of the crypt-villus axis and evolution of its stem cell hierarchy during intestinal development. Am J Physiol. 1995 May; 268(5 Pt 1):G813-22. Hermiston ML, Gordon JI. PMID: 7762665.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimalsCells
    139. In vivo analysis of cadherin function in the mouse intestinal epithelium: essential roles in adhesion, maintenance of differentiation, and regulation of programmed cell death. J Cell Biol. 1995 Apr; 129(2):489-506. Hermiston ML, Gordon JI. PMID: 7721948; PMCID: PMC2199905.
      View in: PubMed   Mentions: 107     Fields:    Translation:AnimalsCells
    140. Differentiation and self-renewal in the mouse gastrointestinal epithelium. Curr Opin Cell Biol. 1994 Dec; 6(6):795-803. Gordon JI, Hermiston ML. PMID: 7880525.
      View in: PubMed   Mentions: 70     Fields:    Translation:AnimalsCells
    141. Chimeric-transgenic mice represent a powerful tool for studying how the proliferation and differentiation programs of intestinal epithelial cell lineages are regulated. Proc Natl Acad Sci U S A. 1993 Oct 01; 90(19):8866-70. Hermiston ML, Green RP, Gordon JI. PMID: 8415622; PMCID: PMC47461.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansAnimalsCells
    142. Use of transgenic mice to characterize the multipotent intestinal stem cell and to analyze regulation of gene expression in various epithelial cell lineages as a function of their position along the cephalocaudal and crypt-to-villus (or crypt-to-surface epithelial cuff) axes of the gut. Seminars in Cell and Developmental Biology. 1993 Oct 1; 4(5):275-291. Hermiston HM, Gordon GJ. .
      View in: Publisher Site   Mentions:
    143. Simultaneous localization of six antigens in single sections of transgenic mouse intestine using a combination of light and fluorescence microscopy. J Histochem Cytochem. 1992 Sep; 40(9):1283-90. Hermiston ML, Latham CB, Gordon JI, Roth KA. PMID: 1506665.
      View in: PubMed   Mentions: 6     Fields:    Translation:Animals
    144. Use of transgenic mice to infer the biological properties of small intestinal stem cells and to examine the lineage relationships of their descendants. Proc Natl Acad Sci U S A. 1991 Nov 01; 88(21):9407-11. Roth KA, Hermiston ML, Gordon JI. PMID: 1946352; PMCID: PMC52726.
      View in: PubMed   Mentions: 16     Fields:    Translation:AnimalsCells
    145. Isolation of mutants defective in early steps of meiotic recombination in the yeast Saccharomyces cerevisiae. Genetics. 1991 May; 128(1):79-88. Malone RE, Bullard S, Hermiston M, Rieger R, Cool M, Galbraith A. PMID: 2060778; PMCID: PMC1204456.
      View in: PubMed   Mentions: 57     Fields:    Translation:Animals